Company news

Novavax, Inc. news in 2021

Novavax, Inc.'s news releases, calls and decks from 2021, newest first.

View company

Novavax Submits Final Data Packages to U.S. FDA as Prerequisite to Emergency Use Authorization Application Request for COVID-19 Vaccine

December 30, 2021

Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in India

December 27, 2021

Novavax and SK bioscience Expand Manufacturing Agreement

December 22, 2021

Novavax Announces Initial Omicron Cross-Reactivity Data from COVID-19 Vaccine Booster and Adolescent Studies

December 21, 2021

World Health Organization SAGE Issues Interim Recommendations for Novavax COVID-19 Vaccine

December 20, 2021

Novavax Announces Initiation of PREVENT-19 COVID-19 Vaccine Phase 3 Trial Booster Study

December 20, 2021

World Health Organization Grants Second Emergency Use Listing for Novavax COVID-19 Vaccine

December 19, 2021

Novavax Receives Positive European Medicines Agency Recommendation for Conditional Marketing Authorization of its COVID-19 Vaccine

December 19, 2021

European Commission Grants Conditional Marketing Authorization for Novavax COVID-19 Vaccine

December 19, 2021

Novavax and Serum Institute of India Announce World Health Organization Grants Emergency Use Listing for NVX-CoV2373 COVID-19 Vaccine

December 16, 2021

Novavax Announces Submission of New Drug Application in Japan for Approval of COVID-19 Vaccine

December 14, 2021

Novavax Files for Emergency Use of COVID-19 Vaccine in the United Arab Emirates

December 12, 2021

Novavax Files for Interim Authorization of COVID-19 Vaccine in Singapore

November 23, 2021

Novavax to Participate in Evercore ISI's 4th Annual HealthCONx Virtual Conference

November 22, 2021

Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in the Philippines

November 16, 2021

Novavax Announces Submission of Biologics License Application in South Korea for Approval of NVX-CoV2373

November 14, 2021

Novavax Reports Third Quarter 2021 Financial Results and Operational Highlights

November 3, 2021

Novavax Files COVID-19 Vaccine for Provisional Approval in New Zealand

November 2, 2021

Novavax Files for COVID-19 Vaccine Authorization with Health Canada and Completes Submission for Rolling Review to European Medicines Agency

October 31, 2021

Novavax Files for Provisional Approval of its COVID-19 Vaccine in Australia

October 28, 2021

Novavax Files for Authorization of its COVID-19 Vaccine in the United Kingdom

October 26, 2021

Novavax Announces Leadership Appointment and Updates

October 3, 2021

Novavax Initiates Phase 1/2 Clinical Trial of Combination Vaccine for COVID-19 and Seasonal Influenza

September 7, 2021

Novavax Statement on CDC Guidance Update for COVID-19 Clinical Trial Participants

August 29, 2021

Novavax to Participate in OCTAVE-DUO Study to Evaluate Third Dose of Vaccine in Participants with Impaired Immune Systems

August 24, 2021

Novavax Appoints Biopharmaceutical Veterans Jim Kelly as Chief Financial Officer and Nasir Egal, Ph.D., as Senior Vice President of Quality Assurance

August 15, 2021

Novavax Reports Second Quarter 2021 Financial Results and Operational Highlights

August 4, 2021

Novavax and European Commission Finalize Advance Purchase Agreement for up to 200 million doses of COVID-19 Vaccine

August 3, 2021

Novavax Announces Positive Results from First Study of Influenza Vaccine and COVID-19 Vaccine Candidate Administered Simultaneously

June 13, 2021

Novavax Announces Positive Data from Three Complementary Studies of COVID-19 Beta (B.1.351) Variant Strain Vaccine

June 10, 2021

Novavax Announces Memorandum of Understanding to Explore Expansion of COVID-19 Vaccine Activities in South Korea

May 21, 2021

Novavax Reports First Quarter 2021 Financial Results and Operational Highlights

May 9, 2021

Novavax and Gavi Execute Advance Purchase Agreement for COVID-19 Vaccine for COVAX Facility

May 5, 2021

Novavax Initiates Pediatric Expansion for Phase 3 Clinical Trial of COVID-19 Vaccine

May 2, 2021

Novavax Announces Leadership Updates

April 12, 2021

Novavax Initiates COVID-19 Vaccine Clinical Trial Crossover

April 4, 2021

Novavax Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights

February 28, 2021

Novavax and Takeda Finalize License Agreement for Novavax’ COVID-19 Vaccine Candidate in Japan; Takeda Initiates Phase 1/2 Trial in Japan

February 25, 2021

Novavax Completes Enrollment of PREVENT-19, COVID-19 Vaccine Pivotal Phase 3 Trial in the United States and Mexico

February 21, 2021

Novavax Announces Memorandum of Understanding with Gavi for Cumulative Supply to COVAX Facility of 1.1 Billion Doses of COVID-19 Vaccine

February 17, 2021

Novavax Announces Expanded Collaboration and License Agreement with SK Bioscience for 40 Million Doses of COVID-19 Vaccine for South Korea

February 14, 2021

Novavax Announces Start of Rolling Review by Multiple Regulatory Authorities for COVID-19 Vaccine Authorization

February 3, 2021

Novavax and Government of Switzerland Announce Agreement in Principle to Supply COVID-19 Vaccine

February 2, 2021

Novavax Announces Memorandum of Understanding to Produce COVID-19 Vaccine Made in Canada

February 1, 2021

Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial

January 27, 2021

Novavax and Government of Canada Finalize Advance Purchase Agreement for COVID-19 Vaccine

January 21, 2021

Regulatory Expert Henrietta Ukwu, M.D. Appointed Novavax Chief Regulatory and Quality Officer

January 14, 2021

Novavax Finalizes Agreement with Commonwealth of Australia for 51 Million Doses of COVID-19 Vaccine

January 6, 2021

Calls in 2021

Decks in 2021